An immense opportunity
CRISPR Therapeutics’ therapy for sickle cell disease could be available next year; this is incredibly exciting news, and the markets are not getting it. We revisit this compelling investment opportunity.
CRISPR technology is one of the big three. So that’s AI, brain-computer interfaces and gene editing — these technologies will be truly transformative over the next few decades.
Of these three technologies, the AI revolution is unravelling now, the brain-computer interface revolution will be more of a 2030s or even 2040s thing, but CRISPR/Cas9 will be receiving the kind of hype mid-decade that we are currently seeing with AI.
As Jennifer Doudna,…
Continue reading our content…
- Unlimited access to our market-beating portfolios
- In-depth coverage of many of the world’s great companies
- Unique insights from our top research team
- Company and markets insights
- Sponsored content
Previous article Next article